肝細胞癌市場:KOL的洞察

本報告提供全球肝細胞癌(HCC)市場相關調查，提供市場概要，以及已通過核准治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

HCC的現在及未來的治療流程

調查目的

免疫療法

• 已通過核准醫藥品
  • TECENTRIQ(Atezolizumab，Roche)+ Avastin(Bevacizumab，Roche)
  • Opdivo(Nivolumab，Bristol Myers Squibb)+ yaboi(Ipilimumab，Bristol Myers Squibb)
  • KEYTRUDA(Pembrolizumab，Merck &Co.)
  • imifinji(Durvalumab，AstraZeneca)+ imujudo(Tremelimumab，AstraZeneca)
• 後期開發平台醫藥品
  • tisurerizumabu(BeiGene/Novartis)
  • kamurerizumabu(Jiangsu Hengrui)
  • jenperi(dosutarimabu，GSK)+ koborimabu(GSK)
  • ributayo(semipurimabu，Regeneron)

蛋白酪氨酸激?抑制劑

• 已通過核准醫藥品
  • nekusabaru(Sorafenib，Bayer)
  • LENVIMA(Lenvatinib，Eisai/Merck & Co)
  • Stivarga(Regorafenib，Bayer)
  • kabometikusu(Cabozantinib，Exelixis/Ipsen)

VEGFR抑制劑

• 已通過核准醫藥品
  • Cyramza(Ramucirumab，Lilly)

其他的作用機制

• 初期階段的開發平台醫藥品
  • Fotivda(chibozanibu，AVEO Oncology)
  • namodenoson(Can-Fite BioPharma)
  • GT90001(Kintor Pharmaceutical)
  • ArtemisT細胞療法(Eureka Therapeutics)
  • MTL-CEBPA(MiNA Therapeutics)
  • fosutorokisashitabinburarupamido/fosutorokusu(Medivir)

HCC治療的未來趨勢與機會

附錄

In what new setting could Roche's Tecentriq + Avastin combination consolidate its standard-of-care position for the first-line treatment of immunotherapy-eligible HCC patients? Why are oncologists optimistic about the read out of the EMERALD-2 trial of AstraZeneca's Imfinzi + Roche's Avastin combination and why might EMERALD-3 trial data cause concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (8)

Current and future treatment algorithm for HCC

Research objectives (2)

Immunotherapy (80)

• Approved drugs (57)
  • Tecentriq (atezolizumab; Roche) + Avastin (bevacizumab; Roche) (12)
  • Opdivo (nivolumab; Bristol Myers Squibb) + Yervoy (ipilimumab; Bristol Myers Squibb) (14)
  • Keytruda (pembrolizumab; Merck & Co.) (19)
  • Imfinzi (durvalumab; AstraZeneca) + Imjudo (tremelimumab; AstraZeneca) (12)
• Late-stage pipeline drugs (23)
  • Tislelizumab (BeiGene/Novartis) (7)
  • Camrelizumab (Jiangsu Hengrui) (5)
  • Jemperli (dostarlimab; GSK) + cobolimab (GSK) (5)
  • Libtayo (cemiplimab; Regeneron) (6)

Tyrosine kinase inhibitors (33)

• Approved drugs (33)
  • Nexavar (sorafenib; Bayer) (8)
  • Lenvima (lenvatinib; Eisai/Merck & Co) (10)
  • Stivarga (regorafenib; Bayer) (9)
  • Cabometyx (cabozantinib; Exelixis/Ipsen) (6)

VEGFR inhibitors (4)

• Approved drugs (4)
  • Cyramza (ramucirumab; Lilly) (4)

Other mechanisms of action (31)

• Early-stage pipeline drugs (31)
  • Fotivda (tivozanib; AVEO Oncology) (6)
  • Namodenoson (Can-Fite BioPharma) (5)
  • GT90001 (Kintor Pharmaceutical) (5)
  • ARTEMIS T-cell therapy (Eureka Therapeutics) (5)
  • MTL-CEBPA (MiNA Therapeutics) (5)
  • Fostroxacitabine bralpamide/fostrox (Medivir) (5)

Future trends and opportunities in HCC treatment (4)

Appendix (7)

• KOL details (7)
  • KOLs from the USA (4)
  • KOLs from Europe (2)